IsomAb evaluate and develop isoform specific antibodies to treat disease.
IsomAb has raised $9.5M in total funding. The most recent round was Seed. The last funding was announced in February 2024.
IsomAb's investors include SCVC, Broadview Ventures, MEIF Proof-of-Concept & Early Stage Fund.
IsomAb is headquartered in Nottingham, United Kingdom.
IsomAb evaluate and develop isoform specific antibodies to treat disease.
IsomAb is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"IsomAb — Funding & Investors." VCBacked, February 20, 2024, https://www.vcbacked.co/company/isomab. Accessed August 14, 2026.
VCBacked. (2024). IsomAb — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/isomab
{{cite web |title=IsomAb — Funding & Investors |url=https://www.vcbacked.co/company/isomab |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated